Skip to main content
Department of Health Department of Health An Roinn Sláinte Männystrie O Pouste

Main navigation

  • Home
  • Topics
  • Publications
  • Consultations
  • Contact

Translation help

Translate this page

Select a language

  • Arabic — عربي
  • Chinese (Simplified) — 中文简体
  • Chinese (Traditional) — 中文繁體
  • Dutch — Nederlands
  • Filipino — Filipino
  • French — Français
  • German — Deutsch
  • Hungarian — Magyar
  • Irish — Gaeilge
  • Italian — Italiano
  • Latvian — Latviešu
  • Lithuanian — Lietuvių kalba
  • Polish — Polski
  • Portuguese — Português
  • Romanian — Română
  • Russian — Русский
  • Slovak — Slovenčina
  • Spanish — Español
  • Ukrainian — Українська
  • NICE - Endorsed Technology Appraisals 2023/2024

    Topics:
    • Safety and quality, 
    • NICE technology appraisals

    It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

    Technology Appraisals Endorsement Process

    The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

    NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

    For information, details of the previous arrangement can be found on the following circular;

    NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

    2023/2024

    The following technology appraisals have been endorsed during 2023/24. Information on technology appraisals endorsed in previous years can be found on the homepage.

    March 2024

    TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over

    TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

    TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

    TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer

    TA950 - Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over

    TA949 - Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over

    February 2024

    TA948 - Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments

    TA947 - Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947 - Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments

    TA946 - Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

    Note this guidance updates and replaces NICE Technology Appraisal TA693, endorsed by the DoH in May 2021.

    TA943 - Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes

    January 2024

    TA944 - Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

    TA942 - Empagliflozin for treating chronic kidney disease

    TA937 - Targeted-release budesonide for treating primary IgA nephropathy

    December 2023

    TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer ‘Note this guidance updates and replaces NICE Technology Appraisal TA885, endorsed by the DoH in May 2023.’

    TA935 - Secukinumab for treating moderate to severe hidradenitis suppurativa

    TA934 - Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms

    TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia

    TA929 - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

    TA928 - Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine

    TA927 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

    TA926 - Baricitinib for treating severe alopecia areata

    TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis

    TA924 - Tirzepatide for treating type 2 diabetes

    TA930 - Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments

    TA922 - Daridorexant for treating long-term insomnia

    TA921 - Ruxolitinib for treating polycythaemia vera

    TA920 - Tofacitinib for treating active ankylosing spondylitis

    TA919 - Rimegepant for treating migraine

    TA918 - Bimekizumab for treating axial spondyloarthritis

    TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

    TA916 - Bimekizumab for treating active psoriatic arthritis

    TA915 - Pegunigalsidase alfa for treating Fabry disease

    TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency

    November 2023

    TA913 - Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy

    TA912 - Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease

    August 2023

    TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer

    TA909 - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

    TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy

    ‘Note this guidance updates and replaces NICE Technology Appraisal TA620, endorsed by the DoH in February 2020.’

    TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis

    TA906 - Rimegepant for preventing migraine

    July 2023

    TA905 - Upadacitinib for previously treated moderately to severely active Crohn’s disease

    TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer

    TA903 - Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer

    TA902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

    TA900 - Tixagevimab plus cilgavimab for preventing COVID-19

    TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

    June 2023

    TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma

    ‘Note this guidance updates and replaces NICE Technology Appraisal TA573, endorsed by the DoH in May 2019.’

    TA896 - Bulevirtide for treating chronic hepatitis D

    TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

    TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma

    TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over

    TA892 - Mosunetuzumab for treating relapsed or refractory follicular lymphoma

    TA891 - Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

    TA890 - Difelikefalin for treating pruritus in people having haemodialysis

    TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease

    TA887 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    ‘Note this guidance updates and replaces NICE Technology Appraisal TA831, endorsed by the DoH in October 2022.’

    TA886 - Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

    May 2023

    TA885 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer ‘Note this guidance has been updated and replaced by TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer, endorsed by the DoH in December 2023.’

    TA883 - Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

    TA882 - Voclosporin with mycophenolate mofetil for treating lupus nephritis

    TA881 - Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments

    TA880 - Tezepelumab for treating severe asthma

    April 2023

    TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

    TA877 - Finerenone for treating chronic kidney disease in type 2 diabetes

    TA876 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer

    TA875 - Semaglutide for managing overweight and obesity

    Related content

    • NICE - Endorsed Technology Appraisals 2006/2007
    • NICE - Endorsed Technology Appraisals 2007/2008
    • NICE - Endorsed Technology Appraisals 2008/2009
    • NICE - Endorsed Technology Appraisals 2009/2010
    • NICE - Endorsed Technology Appraisals 2010/2011
    • NICE - Endorsed Technology Appraisals 2011/2012
    • NICE - Endorsed Technology Appraisals 2012/2013
    • NICE - Endorsed Technology Appraisals 2013/2014
    • NICE - Endorsed Technology Appraisals 2014/2015
    • NICE - Endorsed Technology Appraisals 2015/2016
    • NICE - Endorsed Technology Appraisals 2016/2017
    • NICE - Endorsed Technology Appraisals 2017/2018
    • NICE - Endorsed Technology Appraisals 2018/2019
    • NICE - Endorsed Technology Appraisals 2019/2020
    • NICE - Endorsed Technology Appraisals 2020/2021
    • NICE - Endorsed Technology Appraisals 2021/2022
    • NICE - Endorsed Technology Appraisals 2022/2023
    • NICE - Endorsed Technology Appraisals 2024/2025
    • NICE Technology Appraisals
    Share this page Share on Facebook (external link opens in a new window / tab) Share on X (external link opens in a new window / tab) Share by email (external link opens in a new window / tab)

    Department footer links

    • Crown copyright
    • Terms and Conditions
    • Privacy
    • Cookies
    • Accessibility
    • The Northern Ireland Executive
    • The Executive Office
    • Department of Agriculture, Environment and Rural Affairs
    • Department for Communities
    • Department for Education
    • Department for the Economy
    • Department of Finance
    • Department for Infrastructure
    • Department for Health
    • Department of Justice
    • nidirect.gov.uk — the official government website for Northern Ireland citizens